MILLIONS of Filipinos stand to benefit from the promising results of Covovax, licensed by Novavax, following the global announcement of final efficacy analysis of the United Kingdom (UK) Phase 3 trials of the said vaccine on Tuesday (Philippine time).

Philippine Covovax distributor Faberco Life Sciences, citing the results released by Novavax in the United States today said the vaccine provides 100-percent protection against severe cases of Covid-19 and 96.4-percent efficacy against the original strain of Covid-19.